A PHARMACOECONOMIC EVALUATION OF COST VARIATION AMONG VARIOUS BRANDS OF ANTI-DIABETIC DRUGS CURRENTLY AVAILABLE IN INDIA
DOI:
https://doi.org/10.22159/ajpcr.2023v16i4.49231Keywords:
anti-diabetic drugs, cost variation, pharmacoeconomics, cost ratioAbstract
Objective: Diabetes mellitus is a multisystem disorder affecting almost all the organs of the human body. There are a large number of anti-diabetic drugs available in the Indian market. The cost of the drugs plays an important role in patient’s care, warranting the essential for all physicians to keep themselves updated with the modern prices and price variation of various brands of anti-diabetic drugs.
Methods: Cost of a exact drug (cost per 10 tablets) in the same strength and amount forms being manufactured by different companies was got from the latest editions of “Current Index of Medical Specialties” and “Indian Drug Review”. The percentage price difference and cost ratio for each formulation were intended.
Results: Among non-sulfonylureas, the highest cost variation was found in the drug metformin available in the form of tablet of 500 mg in the Indian pharmaceutical market, a cost ratio of 9.09 was calculated which was highest in the non-sulfonylurea drugs. In sulfonylureas, the highest cost variation was found in the drug glibenclamide having cost ratio of 7.89 in the form of tablet of 5 mg. In combination therapy, the highest percentage cost variation of 432 was found in the fixed-dose combination of glibenclamide+metformin having cost ratio of 5.2.
Conclusion: Our study depicted that there is very high price variation in some of the brands oral anti-diabetic drugs. India being a developing country cannot bear such huge treatment cost of such common lifestyle diseases like diabetes mellitus Type 2. Therefore, a general awareness and proper measures should be taken by controlling authorities, pharmaceutical companies, and treating physicians. Generic prescribing should be promoted in whole country by creating awareness and imposing proper regulatory guidelines
Downloads
References
Tripathi KD. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers (P) LTD.; 2019.
Powers AC. Diabetes mellitus: Diagnosis, classification, and pathophysiology. In: Harrison’s Principles of Internal Medicine. 19th ed., Ch. 417. New York: McGraw-Hill, Health Professions Division; 2015. p. 2399.
Powers AC, D’Alessio DD. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman and Gilman’s: The PharmacologicalBasis of Therapeutics. 13th ed., Ch. 47. New York: McGraw Hill; 2018. p. 868.
Scheen J, Lefebvre PJ. Oral antidiabetic agents. A guide to selection. Drugs 1998;55:225-36.
Jadhav NB, Bhosale MS, Adhav CV. Cost analysis study of oral antidiabetic drugs available in Indian market. Int J Med Res Health Sci 2013;2:63-9.
Paunikar AP, Bhave KA. Cost analysis of oral antidepressant drugs available in India. Natl J Physiol Pharm Pharmacol 2015;5:367-71.
Misra B, Jain SK, Mehta Y. A Study on Availability and Prices of Medicines in India. New Delhi: National Pharmaceutical Pricing Authority; 2002.
Adama T, Evans DB, Murray CJ. Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc 2003;1:3.
Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diabet Med 1997;14 Suppl 5:S1-85.
International Diabetes Federation. Diabetes Complications; 2020. Available from: https://www.idf.org/aboutdiabetes/complications.html [Last accessed on 2020 Apr 15].
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019;157:107843.
WHO. Global Status Report on Non-Communicable Diseases; 2014. Available from: https://www.who.int/nmh/publications/ncd-status-report-2014/en [Last accessed on 2020 Apr 15].
Afroz A, Alramadan MJ, Hossain MN, Romero L, Alam K, Magliano DJ, et al. Cost-of-illness of Type 2 diabetes mellitus in low and lower-middle income countries: A systematic review. BMC Health Serv Res 2018;18:972.
Hu H, Sawhney M, Shi L, Duan S, Yu Y, Wu Z, et al. A systematic review of the direct economic burden of Type 2 diabetes in China. Diabetes Ther 2015;6:7-16.
Singh A, Kumar H. Cost analysis study of second generation antihistamines used in the treatment of allergic rhinitis in India. Int J Basic Clin Pharmacol 2016;5:1228-33.
Dupaguntla R, Gujjarlamudi HB. Pharmacoeconomic evaluation of oral hypoglycemic drugs available in Indian market. Pharma Innov J 2017;6:436-9.
Lalan HN, Borde MK, Ray IM, Deshmukh YA. Cost variation study of antidiabetics: Indian scenario. Indian J Appl Res 2014;4:420-1.
Francis PA. Code for Pharma Marketing. Available from: https://www. pharmabiz.com/ArticleDetails.aspx?aid=85907&sid=3 [Last accessed on 2015 Mar 10].
Deepika PL, Priyambada S. Cost analysis of oral anti‐platelet drugs: A pharmacoeconomic study. Natl J Physiol Pharm Pharmacol 2018;8:215‐8.
Date AP, Mahajan HM, Dashputra AV, Bhosale RR. Study of variation in price of various antidiabetic drugs available in Indian market. Int J Basic Clin Pharmacol 2015;4:36-40.
Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Indian J Pharm Sci 2007;69:158-63.
Deepak KR, Geetha A. Cost variation analysis of various brands of anticoagulants, fibrinolytics, and antiplatelet drugs currently available in Indian pharmaceutical market. Natl J Physiol Pharm Pharmacol 2019;9:368-72.
Shyam S, Mahanthegowda BD. A cost variation analysis of various brands of oral anti-diabetic drugs currently available in Indian pharmaceutical market. Int J Basic Clin Pharmacol 2020;9:1253-7.
Published
How to Cite
Issue
Section
Copyright (c) 2023 MEHUL AGRAWAL, TARUN KUMAR, SWAPNIL MUJUMDAR, NEELESH ARYA
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
